Aromatic Amines and Biomarkers of Human Exposure

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 21, Issue 2, 2003, Pages 133-164

  Talaska, Glenn ^a   Al Zoughool, Mustafa ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Human; Occupational exposure; Susceptibility; Toxicokinetics; Urinary bladder cancer

Indexed keywords

4 AMINOPHENOL; 4,4' METHYLENEBIS(2 CHLOROANILINE); 4,4' METHYLENEDIANILINE; ANILINE DERIVATIVE; AROMATIC AMINE; BIOLOGICAL MARKER; CHEMICAL AGENT; DNA; HEMOGLOBIN; N ACETYLBENZIDINE; N,N' DIACETYLBENZIDINE; TOLUIDINE DERIVATIVE; UNCLASSIFIED DRUG;

BIOLOGICAL MONITORING; BLADDER BIOPSY; BLADDER CARCINOMA; BLOOD ANALYSIS; BREAST CARCINOMA; CANCER PREVENTION; CANCER RISK; DNA ADDUCT; DNA DETERMINATION; ENVIRONMENTAL EXPOSURE; HISTOPATHOLOGY; HUMAN; NONHUMAN; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PROSTATE CARCINOMA; PUBLIC HEALTH; REVIEW; TOXICOKINETICS; UROTHELIUM;

AMINES; AMINOPHENOLS; ANIMALS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARCINOGENS, ENVIRONMENTAL; DNA ADDUCTS; ENVIRONMENTAL EXPOSURE; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 0345708281     PISSN: 10590501     EISSN: None     Source Type: Journal    
DOI: 10.1081/GNC-120026234     Document Type: Review

References (118)

1. ACGIH. Documentation of the TLVs and BEIs. 7th ed. Cincinnati, Ohio, USA: ACGIH, 2002.
2. Forschungsgemeinschaft D. List of MAK and BAT Values 2001. Vol. 37. Federal Republic of Germany: Wiley-VCH, 2001:219 pp.
3. Last JM. Public Health and Preventive Medicine. 11 ed. New York: Appleton Century Crofts 1980:1926 pp.
4. Talaska G. Aromatic amines and human urinary bladder cancer: exposure sources and epidemiology. Environmental Carcinogenesis and Ecotoxicology Reviews 2003; C21:29-44.
5. Bartsch H. Studies on biomarkers in cancer etiology and prevention: a summary and challenge of 20 years of interdisciplinary research. Mutation Research-Reviews in Mutation Research 2000; 462:255-279.
6. Sabbioni G, Jones CR. Biomonitoring of arylamines and nitroarenes. Biomarkers 2002; 7:347-421.
7. Williams JA, Phillips DH. Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res 2000; 60:4667-4677.
8. Kadlubar FF. DNA Adducts of carcinogenic aromatic amines In: Hemminki K, Dipple A, Shuker DEG, Kadlubar FF, Segerback D, Bartsch H. eds. DNA Adducts: Identification and Biological Significance. Vol. 125. Lyon, Fr: IARC Scientific Publications, 1994:199-216.
9. NRC Biological Markers in Pulmonary Toxicology. Washington, D.C: National Academy Press, 1989:179 pp.
10. Frame LT, Ambrosone CB, Kadlubar F, Lang NP. Host-environment interactions that affect variability in human cancer susceptibility In: Neumann DA, Kimmel CA. eds. Human Varibility in Response to Chemical Exposures. Boca Raton, FL: CRC Press, 1998:257 pp.
11. Lee J-H, Roh JH, Burks D, Warshawsky D, Talaska G. Skin cleaning with kerosene facilitates passage of carcinogens to the lungs of animals treated with used gasoline engine oil. Appld Occup Environ Hyg. 2000; 15:362-369.
12. ACGIH. Documentation of the TLVs and BEIs. 8th ed. Cincinnati, OH: American Conference of Governmental Industrial Hygienists, 2003.
13. Jongeneelen FJ. Biological exposure limit for occupational exposure to coal tar pitch volatiles at coke ovens. Int Arch Occup Environ Health 1992; 63:511-516.
14. Van Rooij JGM, Bodelier-Bade MM, Hopmans PMJ. Reduction of urinary 1-hydroxy-pyrene excretion in coke oven workers exposed to polycyclic aromatic hydrocarbons due to improved hygienic skin protective measures. Ann Occup Hyg 1994; 38:247-256.
15. Vermeulen R, Kromhout H, Bruynzeel DP, de BEM, Brunekreef B. Dermal exposure, handwashing, and hand dermatitis in the rubber manufacturing industry. Epidemiology (Cambridge Mass) 2001; 12:350-354.
16. Piotrowski J. Quantitative Estimation of Aniline Absorption Through the Skin in Man. J Hyg Epidemiol Microbiol Immunol 1957; 1:23-33.
17. Poirier M, Fullerton N, Smith B, Beland F. DNA adduct formation and tumorigenesis in mice during the chronic administration of 4-aminobiphenylk at multiple dose levels. Carcinogenesis 1995; 16:2917-2921.
18. Poirier MC, Beland FA. DNA adduct measurements and tumor incidence during chronic carcinogen exposure in animal models: implications from DNA-adduct based human cancer risk assessment. Chem Res Toxicol 1992; 5:749-755.
19. Tsuneoka Y, Dalton TP, Miller MM, Clay CD, Shertzer HG, Talaska G, Medvedovic M, Nebert DW. 4-Aminobiphenyl-Induced Liver and Urinary Bladder DNA Adduct Formation in CYP1A2(-/-) and CYP1A2(+/+) Mice. J Natl Cancer Inst 2003; In Press.
20. Bhatnagar VK, Talaska G. Carcinogen Exposure and Effect Biomarkers. Toxicol Lett 1999; 108:107-116.
21. Hemstreet GPr, Yin S, Ma Z, Bonner RB, Bi W, Rao JY, Zang M, Zheng Q, Bane B, Asal N, Li G, Feng P, Hurst RE, Wang W. Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. Journal of the National Cancer Institute 2001; 93:427-436.
22. Broyde S, Hingerty BE, Srinavasan AR. Influence of the carcinogen 4-aminobiphenyl on DNA conformation. Carcinogenesis 1985; 6:719-725.
23. Talaska G, Au WW, Ward JBJ, Randerath K, Legator MS. The correlation between DNA adducts and chromosomal aberrations in the target organ of benzidine exposed, partially hepatectomized mice. Carcinogenesis 1987; 8:1899-1905.
24. van de Poll MLM, van der Hulst DAM, Tates AD, Mulder GJ, Meerman JHN. Correlation between clastogenicity and promotion activity in liver carcinogenesis by N-hydroxy-2-acetylaminofluorene, N-hydroxy-4′ -fluoro-4-acetylaminobiphenyl, and N-hydroxy-4-acetylaminobiphenyl. Carcinogenesis 1990; 11:333-339.
25. Feng Z, Hyu W, Rom WN, Beland FA, Tag M. 4-Aminobiphenyl is a major etiological agent of human bladder cancer:evidence from its DNA binding spectrum in human p53 gene. Carcinogenesis 2002; 23:1721-1727.
26. Que Hee S. Biological Monitoring. New York: An Introduction Van Norstrand Rheinhold, 1993.
27. Que Hee S. Biological Monitoring In: DiNardi, SR. ed. The Occupational Environment: Its Evaluation and Control. Fairfax, VA, USA: American Industrial Hygiene Association, 1997:262-283.
28. Talaska G. Biological monitoring in occupational health In: Perkins JL, ed. Modern Industrial Hygiene. Vol. 2. Cincinnati: American Conference of Governmental Industrial Hygienists Press, 2003.
29. DeMarini DM, Brooks L, Bhatnagar VK, Hayes RB, Eischen BT, Shelton ML, Zenser TV, Talaska G, Kashyap SK, Dosemeci M, Kashyap R, Parikh DJLV, Hsu F, Davis BB, Jaeger M, Rothman N. Urinary mutagenicity as a biomarker in benzidine-exposed workers: correlation with urinary metabolites and urothelial DNA adducts. Carcinogenesis 1997; 18:981-988.
30. Rothman N, Bhatnagar VK, Hayes RB, Kashyap R, Parikh DJ, Kashyap SK, Schulte PA, Butler MA, Jaeger M, Talaska G, The impact of interindividual variability in N-acetyl-transferase activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers. Proc Natl Acad Sci USA 1996; 93:5084-5089.
31. Tsuneoka Y, Dalton TP, Miller ML, Clay CD, Shertzer HG, Talaska G, Medvedovic M, Nebert DW. 4-Aminobiphenyl-induced liver and urinary bladder DNA adduct formation in CYP1A2(-/-) and CYP1A2(+/+) Mice. J Nat Cancer Inst. 2003; In Press.
32. Ross RK, Yuan J-M, Yu MC, Wogan GN, Qian G-S, Tu J-T, Groopman JD, Gao Y-T, Henderson BE. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339:943-946.
33. Barker PE. Cancer biomarker validation: standards and process: roles for the national institute of standards and technology (NIST). Annals New York Acad Sci 2003; 983:142-150.
34. Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiology Biomarkers & Prevention 2000; 9:3-28.
35. Bi W, Hayes RB, Feng P, Qi Y, You X, Zhen J, Zheng M, Qu B, Fu Z, Chen M, Chein HTWJB. Mortality and cancer incidence of bladder cancer of benzidine-exposed workers in China. Am J Ind Med 1992; 21:481-489.
36. Bryant MS, Vineis P, Skipper P, Tannenbaum SR. Hemoglobin adducts of aromatic amines: associations with smoking status and type of tobacco. Proc Natl Acad Sci USA 1988; 85:9788-9791.
37. Dallinga JW, Pachen D, Wijnhoven SWP, Breedijk A, van't Veer L, Wigbout G, van Zandwijk N, Maas LM, van Agen E, Kleinjans JCS, van Schooten FJ. The use of 4-aminobiphenyl hemoglobin adducts and aromatic DNA adducts in lymphocytes of smokers as biomarkers of exposure. Cancer Epidemiology Biomarkers & Prevention 1998; 7:571-577.
38. Marcus P, Hayes R, Vineis P, Garcia-Closas M, Caporaso N, Autrup H, Branch R, Brockmoller J, Ishizaki T, Karakaya A, Ladero J, Mommsen S, Okkels H, Romkes M, Roots I, Rothman N. Cigarette smoking, N-actetytransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 2000; 9:461-467.
39. 32P-Postlabelling analysis of DNA adducted with urinary mutagens from smokers of black tobacco. Carcinogenesis 1990; 11:1307-1311.
40. Riffelmann M, Muller G, Schmieding W, Popp W, Norpoth K. Biomonitoring of urinary aromatic amines and arylamine hemoglobin adducts in exposed workers and nonexposed control persons. Int Arch Occup Environ Health 1995; 68:36-43.
41. Talaska G, Al-Juburi AZSS, Kadlubar FF. Smoking-related carcinogen-DNA adducts in biopsy samples of human urinary bladder: identification of N-deoxyguanosin-8-yl-4-aminobiphenyl as a major adduct. Proc Natl Acad Sci USA 1991; 88:5350-5354.
42. Skipper P, Tannenbaum S, Ross RK, Yu MC. Nonsmoking related arylamine exposure and bladder cancer risk. Cancer Epidemiol. Biomarkers Prevention 2003; 12:503-507.
43. Dixon WJ, Massey FJJ. Introduction to Statistical Analysis. Boston: McGraw-Hill, 1969.
44. Brown KK, Teass AW, Simon S, Ward EM. A biological monitoring method for o-toluidine and aniline in urine using high performance liquid chromatography with electrochemical detection. Appl Occup Environ Hyg 1995; 10:557-566.
45. 32P-Postlabelling analysis of DNA adducts of 4,4′-methylene bis(2-chloraniline) in target and nontarget tissues in the dog and their implications for human risk assessment. Carcinogenesis 1993; 14:2143-2147.
46. Segerback D, Kadlubar FF. Characterization of 4,4′-methylene bis(2chloroaniline)-DNA adducts formed in vitro and in vivo. Carcinogenesis 1992; 13:1587-1592.
47. Chapp DE, Piacitelli GM, Zaebst DD, Ward EM. Assessing exposure to 4,4′-methylene bis(2-chloroaniline) (MBOCA) in the workplace. Appl Occup Environ Hyg 1991; 6:125-130.
48. Lowry LK, Clapp DE. Urinary 4,4′-methylene bis(2-chloroaniline) (MBOCA): a case for biological monitoring. Appl Occup Environ Hyg 1992; 7:593-598.
49. Ducos P, Maire C, Gaudin R. Assessment of occupational exposure to 4,4′-methylene bis(2-chloroaniline). Int Arch Occup Environ Health 1985; 55:159-167.
50. Cocker J, Nutley BP, Wilson HK. Methylene bis(2-chloroaniline) (MBOCA): towards a biological monitoring guidance value. Biomarkers 1996; 1:185-189.
51. Cocker J, Nutley BP, Wilson HK. A biological monitoring assessment of exposure to methylene dianiline manufacturersand users. Occupational and Environmental Medicine 1994; 51:519-522.
52. Dewan A, Jani JP, Patel JS, Gandhi DN, Variya MR, Ghodasara NB. Benzidine and its acetylated metabolites in the urine of workers exposed to Direct Black 38. Arch Environ Health 1988; 43:269-272.
53. Babu SR, Lakshmi VM, Huang GP, Zenser TV, Davis BB. Glucuronide conjugates of 4-aminobiphenyl and its N-hydroxy metabolites. pH stability and synthesis by human and dog liver. Biochem Pharmacol 1996; 51:1679-1685.
54. Rothman N, Hayes RB, Zenser TV, DeMarini DM, Bi W, Hirvonen A, Talaska G, Bhatnagar VK, Caporaso N, Brooks L, Lakshmi V, Feng P, Kashyap SK, You X, Eischen BT, Kashyap R, Shelton ML, Hsu F, Jaeger M, Parikh DJ, Davis B, Yin S, Bell DA. The impact of Glutathione-S-Transferase M1 (GSTM1) null genotype on benzidine-associated bladder cancer, Urine mutagenicity and exfoliated urothelial cell DNA adducts. Cancer Epidemiol Biomarkers Prevention 1996; 5:979-983.
55. Ward EM, Sabbioni G, DeBord DG, Teass AW, Brown KK, Talaska GG, Roberts DR, Ruder AM, Streicher RP. Monitoring of aromatic amine exposures in workers at a chemical plant with a known bladder cancer excess. J Natl Cancer Inst 1996; 88:1046-1052.
56. Ciotti M, Lakshmi VM, Basu N, Davis BB, Owens IS, Zenser TV. Glucuronidation of benzidine and its metabolites by cDNA-expressed human UDP-glucuronosyltransferases and pH stability of glucuronides. Carcinogenesis 1999; 20:1963-1969.
57. Probst-Hensch NM, Bell DA, Watson MA, Skipper PL, Tannenbaum SR, Chan KK, Ross RK, Yu MC. N-Acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiology Biomarkers & Prevention 2000; 9:619-623.
58. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar F, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska G, Tannenbaum SR. Genetically-based N-acetyltransferase metabolic polymorphism and low level environmental exposure to carcinogens. Nature (London) 1994; 369:254-256.
59. Vineis P, Pirastu R. Aromatic amines and cancer. Cancer Causes Control 1997; 8:346-355.
60. Bryant MS, Skipper PL, Tannenbaum SR, Maclure M. Hemoglobin adducts of 4-aminobiphenyl in smokers and nonsmokers. Cancer Res 1987; 47:602-608.
61. Kadlubar FF, Dooley KL, CHT, Roberts DW, Benson RW, Butler MA, Bailey JR, Young JF, PWS, Tannenbaum SR. Frequency of urination and its effect on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in beagle dogs given the carcinogen 4-aminobiphenyl. Cancer Res 1991; 51:4371-4377.
62. Kadlubar FF, Dooley KL, Teitel CH, Roberts DW, Benson RW, Butler MA, Bailey JR, Young JF, Skipper PW, Tannenbaum SR. Effects of voiding interval on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in Beagle dogs administered the carcinogen, 4-aminobiphenyl. Cancer Res 1991; 51:4371-4377.
63. Kadlubar FF, Miller JA, Miller EC. Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxylarylamines in relation to urinary bladder carcinogenesis. Cancer Res 1977; 37:805-814.
64. Talaska G, Schamer M, Skipper P, Tannenbaum S, Caporaso N, Unruh L, Kadlubar F, Bartsch H, Malaveille C, Vineis P. Detection of carcinogen-DNA adducts in exfoliated urothelial cells of cigarette smokers: correlation with smoking, hemoglobin adducts, and urinary mutagenicity. Cancer Epidemiol Biomarkers Prevention 1991; 1:61-66.
65. 32P]postlabelling and subsequent thin layer- and high pressure liquid chromatography. Carcinogenesis 1990; 11:639-646.
66. Birner G, Albrecht W, Neumann HG. Biomonitoring of aromatic amines III: Hemoglobin binding of benzidine and some benzidine congeners. Arch Toxicol 1990; 64:97-102.
67. Kautiainen A, Wachtmeister CA, Ehrenberg L. Characterization of hemoglobin adducts from a 4, 4′-methylenedianiline metabolite evidently produced by peroxidative oxidation in vivo. Chemical Res Toxicol 1998; 11:614-621.
68. Sabbioni G, Beyerbach A. Haemoglobin adducts of aromatic amines: diamines and polyaromatic amines. J Chromatography B Biomedical Sci Appl 2000; 744:377-387.
69. Sabbioni G, Schutze D. Hemoglobin binding of bicyclic aromatic amines. Chem Res Toxicol 1998; 11:471-483.
70. Neumann HG, Albrecht O, van DC, Zwirner-Baier I. Macromolecular adducts caused by environmental chemicals. Clin Chem 1995; 41:1835-1840.
71. Richter E, Rosler S, Scherer G, Gostomzyk JG, Grubl A, Kramer U, Behrendt H. Haemoglobin adducts from aromatic amines in children in relation to area of residence and exposure to environmental tobacco smoke. Int Arch Occup Environ Health 2001; 74:421-428.
72. Thier R, Lewalter J, Selinski S, Bolt HM. Biological monitoring in workers in a nitrobenzene reduction plant: haemoglobin versus serum albumin adducts. Int Arch Occup Environ Health 2001; 74:483-488.
73. Bryant MS, Simmons HF, Harrell RE, Hinson JA. 2,6-Dimethylaniline-hemoglobin adducts from lidocaine in humans. Carcinogenesis 1994; 15:2287-2290.
74. Bartsch H, Caporaso N, Coda M, Kadlubar FF, Malaveille C, Skipper P, Talaska G, Tannenbaum SR, Vineis P. Carcinogen-hemoglobin adducts, urine mutagenicity and metabolic phenotype in active and passive cigarette smokers. J Natl Cancer Inst 1990; 82:1826-1830.
75. Vineis P, Caporaso N, Tannenbaum S, Skipper P, Glogowski J, Bartsch H, Coda M, Talaska G, Kadlubar F. Acetylation phenotype, carcinogen-hemoglobin adducts, and cigarette-smoking. Cancer Res 1990; 50:3002-3004.
76. Maclure M, Bryant MS, Skipper P, Tannenbaum S. Decline of the hemoglobin adduct of 4-aminobiphenyl during withdrawal from smoking. Cancer Res 1990; 50:181-184.
77. Weston A, Caparaso NE, Taghizadeh K, Hoover RN, Tannenbaum S, Skipper P, Resau JH, Trump BF, Harris CC. Measurement of 4-aminobiphenyl hemoglobin adducts in cancer cases and controls. Cancer Res 1991; 51:5219-5223.
78. Castelao JE, Yuan J-M, Skipper P, Tannenbaum SR, Gado-Dominguez M, Crowder JS, Ross RK, Yu MC. Gender- and smoking-related bladder cancer risk. J Natl Cancer Inst 2001; 93:538-545.
79. Tang D, Warburton D, Tannenbaum S, Skipper P, Santella RM, Cereijido GS, Crawford FG, Perera FP. Molecular and genetic damage from environmental tobacco smoke in young children. Cancer Epidemiol Biomarkers Prevention 1999; 8:427-431.
80. Liu YY, Yao M, Fang J-L, Wang Y-W. Monitoring human risk and exposure to trinitrotoluene using haemoglobin adducts as biomarkers. Toxicol Letts 1995; 77:281-287.
81. Boogaard PJ, Beulink GD, van Sittert NJ. Biological monitoring of exposure to 3-chloro-4-fluoroaniline by determination of a urinary metabolite and a hemoglobin adduct. Environ Health Perspect 1994; 102:23-25.
82. Zhou Q, Talaska G, Jaeger M, Bhatnagar VK, Hayes RB, Zenzer TV, Kashyap SK, Lakshmi VM, Kashyap R, Dosemeci M, Hsu FF, Parikh DJ, Davis B, Rothman N, Benzidine-DNA adduct levels in human peripheral white blood cells significantly correlate with levels in exfoliated urothelial cells. Mutat Res 1997; 393:199-205.
83. Wiencke JK, Kelsey KT, Varkonyi A, Semey K, Wain J, Eugene M, Christiani DC. Correlation of DNA adducts in blood mononuclear cells with tobacco carcinogen-induced damage in human lung. Cancer Res 1995; 55:4910-4914.
84. Airoldi L, Orsi F, Magagnotti C, Coda R, Randone D, Casetta G, Peluso M, Hautefeuille A, Malaveille C, Vineis P. Determinants of 4-aminobiphenyl-DNA adducts in bladder cancer biopsies. Carcinogenesis 2002; 23:861-866.
85. Curigliano G, Zhang Y, Wang L, Flamini G, Alcini A, Ratto C, Giustacchini M, Alcini E, Cittadini A, Santella R. Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. Carcinogenesis 1996; 17:911-916.
86. Martone T, Airoldi L, Magagnotti C, Coda R, Randone D, Malaveille C, Avanzi G, Merletti F, Hautefeuille A, Vineis P. 4-Aminobiphenyl-DNA adducts and p53 mutations in bladder cancer. Int J Cancer 1998; 75:512-516.
87. Flamini G, Romano G, Curigliano G, Chiominto A, Capelli G, Boninsegna A, Signorelli C, Ventura L, Santella R, Sgambato A, Cittadini A. 4-Aminobiphenyl-DNA adducts in laryngeal tissue and smoking habits: an immunohistochemical study. Carcinogenesis 1998; 19:353-357.
88. Lin D, Lay JO, Bryant MS, Malaveille C, Friesen M, Bartsch H, Lang NP, Kadlubar FF. Analysis of 4-aminobiphenyl-DNA adducts in human urinary bladder and lung by alkaline hydrolysis and negative ion gas chromatographymass spectrometry. Environ Health Perspect 1994; 102:11-16.
89. Hsu T-M, Zhang Y-J, Santella R. Immunoperoxidase quantitation of 4-aminobiphenyl and polycyclic aromatic hydrocarbon DNA adducts in exfoliated oral and urothelial cells of smokers and nonsmokers. Cancer Epidemiol Biomarkers Prevention 1997; 6:193-199.
90. 32P-postlabelling. Cancer Epidemiol Biomarkers Prevention 1993; 2:63-69.
91. Boeniger MF, Lowry LK, Tolos WP. Environmental levels and urin content of workers exposed to azo dyes NCI/EPA/NIOSH Collaborative workshop: progress in joint environmental and occupational cancer studies. Rockville, MD: US CDC, 1980.
92. Vermeulen R, Talaska G, Schumann B, Bos RP, Rothman N, Kromhout H. Urothelial cell DNA adducts in rubber manufacturing workers. Environ Mol Mutatgen 2002; 39:306-313.
93. Gorlewska-Roberts K, Green B, Fares M, Ambrosone CB, Kadlubar FF. Carcinogen-DNA adducts in human breast epithelial cells. Environ Mol Mutatgen 2002; 39:184-192.
94. Rundle A, Schwartz S. Issues in the epidemiological analysis and interpretation of intermediate biomarkers. Cancer Epidemiol Biomarkers Prevention 2003; 12:491-496.
95. Garte S. Metabolic susceptibility genes as cancer risk factors: time for a reassessment? Cancer Epidemiol. Biomarkers Prev 2001; 10:1233-1237.
96. Kadlubar FF, Badawi AF. Genetic susceptibility and carcinogen-DNA adduct formation in human urinary bladder carcinogenesis. Toxicol Letts 1995; 82/83:627-632.
97. Butler MA, Guengerich FP, Kadlubar FF. Metabolic oxidation of the carcinogens 4-aminobiphenyl and 4,4′-methylenebis-2-chloroaniline by human hepatic microsomes and by purified rat hepatic cytochrome P-450 monooxygenases. Cancer Res 1989; 49:25-31.
98. Butler MA, Ivasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450paP-4501A2, the phenacetin-O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989; 86:7696-7700.
99. Guengrich FP, Parikh A, Turesky RJ, Josephy PD. Inter-individual differences i the metabolism of environmental toxicants: cytochrome P450 1A2 as a prototype. Mutat Res 1999; 428:115-124.
100. Liang, Li H, McKinnon RA, Duffy JJ, Potter SS, Puga A, Nebert DW. Cypla2 (-/-) null mutant mice develop normall, ut show deficient drug metabolism. Proc Natl Acad Sci USA 1996; 93:1671-1676.
101. Uno S, Dalton TP, Shertzer HG, Genter MB, Warshawsky D, Talaska G, Nebert DW. Benzo[a]pyrene-induced toxicity: paradoxical protection in Cyplal(-/-) knockout mice having increased hepatic BaP-DNA adduct levels. Biochem Biophys Res Commun 2001; 289:1049-1056.
102. Orzechowski A, Schrenk D, Bock-Hennig BS, Bock KW. Glucuronidation of carcinogenic arylamines and their N-hydroxyderivatives by rat and human phenol UDP-glucuronosyltransferase of the UGT1 gene complex. Carcinogenesis 1994; 15:1549-1553.
103. Zenser TV, Lakshmi VM, Davis BB. N-Glucuronidation of benzidine and its metabolites. Role in bladder cancer. Drug Metab Disposition 1998; 26:856-859.
104. Rothman N, Talaska G, Hayes RB, Bhatnagar VK, Bell DA, Lakshmi VM, Kashyap SK, Dosemeci M, Kashyap R, Hsu FF, Jaeger M, Hirvonen A, Parikh DJ, Davis BB, Zenser TV. Acidic urine pH is associated with elevated levels of free urinary benzidine and N-acetylbenzidine and urothelial cell DNA adducts in exposed workers. Cancer Epidemiology Biomarkers & Prevention 1997; 6:1039-1042.
105. Hsu FF, Lakshmi V, Rothman N, Bhatnagar VK, Hayes RB, Kashyap R, Parikh DJ, Kashyap SK, Turk J, Zenser TV, Davis B. Determination of benzidine, N-acetylbenzidine and N,N'-diacetylbenzidine in human urine by capillary gas chromatography negative ion chemical ionization mass spectrometry. Anal Biochem 1996; 234:183-189.
106. DeBruin LS, Josephy PD, Pawliszyn JB. Solid stage microextraction of aromatica amines for biological fluids. Anal Chem 1998; 70:1986-1992.
107. DeBruin LS, Pawliszyn JB, Josephy PD. Detection of monocyclic aromatic amines, possibly mammary carcinogens, in human milk. Chem Res Toxicol 1999; 12:78-82.
108. El-Marbouh L, Arellano C, Phillibert C, Evrard P, Poey J, Houin G. Development and evaluation of an HPLC urinalysis screening test for occupational exposure to 3,4-and 3,5-dichloroanilines. Int J Clin Pharmacol Therap 2002; 40:41-46.
109. Vineis P, Talaska G, Malaveille C, Bartsch H, Martone T, Sithisarankul P, Strickland P. DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and aromatic hydrocarbons from tobacco smoke. Int J Cancer 1996; 65:314-316.
110. Anderson D. Factors contributing to biomarker responses in exposed workers. Mutat Res 1999; 428:197-202.
111. Fenech M, Holland N, Chang WP, Zeiger E, Bonassi S. The human MicroNucleus project - an international collaborative study on the use of the micronucleus technique for measuring DNA damage in humans. Mutat Res 1999; 428:271-283.
112. Maffei F, Angelini S, Forti GC, Lodi V, Violante FS, Mattioli S, Hrelia P. Micronuclei frequencies in hospital workers occupationally exposed to low levels of ionizing radiation: influence of smoking status and other factors. Mutagenesis 2002; 17:405-409.
113. Nersesyan AK. Re: biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst 2001; 93:1492-1493.
114. Sram RJ. Effect of glutathione S-transferase M1 polymorphisms on biomarkers of exposure and effects. Environ Health Persp 1998; 106(suppl 1):231-239.
115. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003; 95:661-668.
116. Vainio H. Use of biomarkers-new frontiers in occupational toxicology and epidemiology. Toxicol Lett 1998; 103:581-589.
117. Vainio H. Use of biomarkers in risk assessment. International Journal of Hygiene and Environmental Health 2001; 204:91-102.
118. Heim S, Mitelman F. Cancer cytogenetics. New York: Chromosomal and molecular genetic aberrations of tumor cells Wiley-Liss, 1995.